+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Deferiprone Market By Form: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 280 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994240
Description Jump to:
The deferiprone market was valued at $33.4 million in 2023 and is projected to reach $45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.

Deferiprone is a compound used as a medication for curing iron overload caused by blood transfusions or thalassemia major. The role of deferiprone involves the chelation of iron and its removal from the bloodstream through urine. Deferiprone is consumed as a tablet or oral solution and is readily absorbed by the upper gastrointestinal tract.

The growth of the deferiprone market is significantly driven by increase in the prevalence of diseases that require regular blood transfusions such as thalassemia and sickle cell anemia. In addition, rise in awareness regarding iron disorders is boosting the adoption of deferiprone for iron overload cases. Furthermore, governments in several countries are focusing on the improvement of treatment capabilities for chronic diseases and iron-related disorders, which is upsurging the demand for deferiprone. This is propelling the development of the market. Currently, explorations regarding expansion of the applications of deferiprone are trending in the market. According to an article posted on the American Association for Cancer Research Journals, deferiprone is anticipated to act as an alternative immunotherapeutic drug for the control of metastatic ovarian cancer.

However, improper or excessive dosage of deferiprone leads to severe side effects such as agranulocytosis and neutropenia, limiting its utility and hampering the growth of the market. Furthermore, the medication faces stringent competition from equally efficient alternatives such as desferrioxamine and deferasirox. This restrains the development of the deferiprone market considerably. Contrarily, rise in the popularity of personalized medicine is projected to present new avenues for the market. Personalized medicine involves providing medications and treatments specifically according to an individual’s health and body condition. This is projected to boost the uptake of deferiprone as tailored dosages have minimum to no possibility of causing side effects to the human body.

Segment Review

The deferiprone market is segmented into form, application, distribution channel, and region. On the basis of form, the market is bifurcated into tablets and others. As per application, it is divided into transfusional iron overload and NTDT caused overload. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023.

As per application, the transfusional iron overload segment is anticipated to account for a high market share by 2033.

Depending on distribution channel, the online providers segment is projected to be the highest shareholder throughout the forecast period.

Region wise, North America was the highest revenue generator in the market in 2023.

Competition Analysis

The key players operating in the global deferiprone market include Apotex Inc, Cipla Limited, VHB Life Sciences Limited, Taro Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Novartis International AG, Chiesi Farmaceutici S.p.A, Zydus Cadila, Cipla Inc., and Pfizer. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Form

  • Tablets
  • Others

By Application

  • Transfusional Iron Overload
  • NTDT Caused Overload.

By Distribution Channel

  • Hospital Pharmacies
  • Drug store retail pharmacies
  • Online providers

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
Key Market Players
  • Apotex Inc
  • Cipla Limited
  • VHB Life Sciences Limited
  • Taro Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Chiesi Farmaceutici S.p.A
  • Zydus Cadila
  • Cipla Inc.
  • Pfizer

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: DEFERIPRONE MARKET, BY FORM
4.1. Market Overview
4.1.1 Market Size and Forecast, By Form
4.2. Tablets
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Others
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: DEFERIPRONE MARKET, BY APPLICATION
5.1. Market Overview
5.1.1 Market Size and Forecast, By Application
5.2. Transfusional Iron Overload
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. NTDT Caused Overload.
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: DEFERIPRONE MARKET, BY DISTRIBUTION CHANNEL
6.1. Market Overview
6.1.1 Market Size and Forecast, By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Drug Store Retail Pharmacies
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Online Providers
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: DEFERIPRONE MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Form
7.2.3. Market Size and Forecast, By Application
7.2.4. Market Size and Forecast, By Distribution Channel
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Deferiprone Market
7.2.6.1. Market Size and Forecast, By Form
7.2.6.2. Market Size and Forecast, By Application
7.2.6.3. Market Size and Forecast, By Distribution Channel
7.2.7. Canada Deferiprone Market
7.2.7.1. Market Size and Forecast, By Form
7.2.7.2. Market Size and Forecast, By Application
7.2.7.3. Market Size and Forecast, By Distribution Channel
7.2.8. Mexico Deferiprone Market
7.2.8.1. Market Size and Forecast, By Form
7.2.8.2. Market Size and Forecast, By Application
7.2.8.3. Market Size and Forecast, By Distribution Channel
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Form
7.3.3. Market Size and Forecast, By Application
7.3.4. Market Size and Forecast, By Distribution Channel
7.3.5. Market Size and Forecast, By Country
7.3.6. France Deferiprone Market
7.3.6.1. Market Size and Forecast, By Form
7.3.6.2. Market Size and Forecast, By Application
7.3.6.3. Market Size and Forecast, By Distribution Channel
7.3.7. Germany Deferiprone Market
7.3.7.1. Market Size and Forecast, By Form
7.3.7.2. Market Size and Forecast, By Application
7.3.7.3. Market Size and Forecast, By Distribution Channel
7.3.8. Italy Deferiprone Market
7.3.8.1. Market Size and Forecast, By Form
7.3.8.2. Market Size and Forecast, By Application
7.3.8.3. Market Size and Forecast, By Distribution Channel
7.3.9. Spain Deferiprone Market
7.3.9.1. Market Size and Forecast, By Form
7.3.9.2. Market Size and Forecast, By Application
7.3.9.3. Market Size and Forecast, By Distribution Channel
7.3.10. UK Deferiprone Market
7.3.10.1. Market Size and Forecast, By Form
7.3.10.2. Market Size and Forecast, By Application
7.3.10.3. Market Size and Forecast, By Distribution Channel
7.3.11. Rest of Europe Deferiprone Market
7.3.11.1. Market Size and Forecast, By Form
7.3.11.2. Market Size and Forecast, By Application
7.3.11.3. Market Size and Forecast, By Distribution Channel
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Form
7.4.3. Market Size and Forecast, By Application
7.4.4. Market Size and Forecast, By Distribution Channel
7.4.5. Market Size and Forecast, By Country
7.4.6. China Deferiprone Market
7.4.6.1. Market Size and Forecast, By Form
7.4.6.2. Market Size and Forecast, By Application
7.4.6.3. Market Size and Forecast, By Distribution Channel
7.4.7. Japan Deferiprone Market
7.4.7.1. Market Size and Forecast, By Form
7.4.7.2. Market Size and Forecast, By Application
7.4.7.3. Market Size and Forecast, By Distribution Channel
7.4.8. India Deferiprone Market
7.4.8.1. Market Size and Forecast, By Form
7.4.8.2. Market Size and Forecast, By Application
7.4.8.3. Market Size and Forecast, By Distribution Channel
7.4.9. South Korea Deferiprone Market
7.4.9.1. Market Size and Forecast, By Form
7.4.9.2. Market Size and Forecast, By Application
7.4.9.3. Market Size and Forecast, By Distribution Channel
7.4.10. Australia Deferiprone Market
7.4.10.1. Market Size and Forecast, By Form
7.4.10.2. Market Size and Forecast, By Application
7.4.10.3. Market Size and Forecast, By Distribution Channel
7.4.11. Rest of Asia-Pacific Deferiprone Market
7.4.11.1. Market Size and Forecast, By Form
7.4.11.2. Market Size and Forecast, By Application
7.4.11.3. Market Size and Forecast, By Distribution Channel
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Form
7.5.3. Market Size and Forecast, By Application
7.5.4. Market Size and Forecast, By Distribution Channel
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Deferiprone Market
7.5.6.1. Market Size and Forecast, By Form
7.5.6.2. Market Size and Forecast, By Application
7.5.6.3. Market Size and Forecast, By Distribution Channel
7.5.7. South Africa Deferiprone Market
7.5.7.1. Market Size and Forecast, By Form
7.5.7.2. Market Size and Forecast, By Application
7.5.7.3. Market Size and Forecast, By Distribution Channel
7.5.8. Saudi Arabia Deferiprone Market
7.5.8.1. Market Size and Forecast, By Form
7.5.8.2. Market Size and Forecast, By Application
7.5.8.3. Market Size and Forecast, By Distribution Channel
7.5.9. Rest of LAMEA Deferiprone Market
7.5.9.1. Market Size and Forecast, By Form
7.5.9.2. Market Size and Forecast, By Application
7.5.9.3. Market Size and Forecast, By Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. Apotex Inc
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Cipla Limited
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. VHB Life Sciences Limited
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Taro Pharmaceutical Industries Ltd.
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Sun Pharmaceutical Industries Ltd.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Novartis International AG
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Chiesi Farmaceutici S.p.A
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Zydus Cadila
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Cipla Inc.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Pfizer
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
Table 1. Global Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 2. Deferiprone Market for Tablets, by Region, 2024 - 2033 ($Million)
Table 3. Deferiprone Market for Others, by Region, 2024 - 2033 ($Million)
Table 4. Global Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 5. Deferiprone Market for Transfusional Iron Overload, by Region, 2024 - 2033 ($Million)
Table 6. Deferiprone Market for Ntdt Caused Overload. by Region, 2024 - 2033 ($Million)
Table 7. Global Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 8. Deferiprone Market for Hospital Pharmacies, by Region, 2024 - 2033 ($Million)
Table 9. Deferiprone Market for Drug Store Retail Pharmacies, by Region, 2024 - 2033 ($Million)
Table 10. Deferiprone Market for Online Providers, by Region, 2024 - 2033 ($Million)
Table 11. Deferiprone Market, by Region, 2024 - 2033 ($Million)
Table 12. North America Deferiprone Market, by Country, 2024 - 2033 ($Million)
Table 13. North America Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 14. North America Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 15. North America Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 16. U.S. Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 17. U.S. Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 18. U.S. Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 19. Canada Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 20. Canada Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 21. Canada Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 22. Mexico Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 23. Mexico Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 24. Mexico Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 25. Europe Deferiprone Market, by Country, 2024 - 2033 ($Million)
Table 26. Europe Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 27. Europe Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 28. Europe Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 29. France Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 30. France Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 31. France Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 32. Germany Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 33. Germany Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 34. Germany Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 35. Italy Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 36. Italy Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 37. Italy Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 38. Spain Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 39. Spain Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 40. Spain Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 41. UK Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 42. UK Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 43. UK Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 44. Rest of Europe Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 45. Rest of Europe Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 46. Rest of Europe Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 47. Asia-Pacific Deferiprone Market, by Country, 2024 - 2033 ($Million)
Table 48. Asia-Pacific Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 49. Asia-Pacific Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 50. Asia-Pacific Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 51. China Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 52. China Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 53. China Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 54. Japan Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 55. Japan Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 56. Japan Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 57. India Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 58. India Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 59. India Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 60. South Korea Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 61. South Korea Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 62. South Korea Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 63. Australia Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 64. Australia Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 65. Australia Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 66. Rest of Asia-Pacific Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 67. Rest of Asia-Pacific Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 68. Rest of Asia-Pacific Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 69. LAMEA Deferiprone Market, by Country, 2024 - 2033 ($Million)
Table 70. LAMEA Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 71. LAMEA Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 72. LAMEA Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 73. Brazil Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 74. Brazil Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 75. Brazil Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 76. South Africa Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 77. South Africa Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 78. South Africa Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 79. Saudi Arabia Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 80. Saudi Arabia Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 81. Saudi Arabia Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 82. Rest of LAMEA Deferiprone Market, by Form, 2024 - 2033 ($Million)
Table 83. Rest of LAMEA Deferiprone Market, by Application, 2024 - 2033 ($Million)
Table 84. Rest of LAMEA Deferiprone Market, by Distribution Channel, 2024 - 2033 ($Million)
Table 85. Apotex Inc.: Key Executives
Table 86. Apotex Inc.: Company Snapshot
Table 87. Apotex Inc.: Operating Segments
Table 88. Apotex Inc.: Product Portfolio
Table 89. Apotex Inc.: Key Strategic Moves and Developments
Table 90. Cipla Limited: Key Executives
Table 91. Cipla Limited: Company Snapshot
Table 92. Cipla Limited: Operating Segments
Table 93. Cipla Limited: Product Portfolio
Table 94. Cipla Limited: Key Strategic Moves and Developments
Table 95. Vhb Life Sciences Limited: Key Executives
Table 96. Vhb Life Sciences Limited: Company Snapshot
Table 97. Vhb Life Sciences Limited: Operating Segments
Table 98. Vhb Life Sciences Limited: Product Portfolio
Table 99. Vhb Life Sciences Limited: Key Strategic Moves and Developments
Table 100. Taro Pharmaceutical Industries Ltd.: Key Executives
Table 101. Taro Pharmaceutical Industries Ltd.: Company Snapshot
Table 102. Taro Pharmaceutical Industries Ltd.: Operating Segments
Table 103. Taro Pharmaceutical Industries Ltd.: Product Portfolio
Table 104. Taro Pharmaceutical Industries Ltd.: Key Strategic Moves and Developments
Table 105. Sun Pharmaceutical Industries Ltd.: Key Executives
Table 106. Sun Pharmaceutical Industries Ltd.: Company Snapshot
Table 107. Sun Pharmaceutical Industries Ltd.: Operating Segments
Table 108. Sun Pharmaceutical Industries Ltd.: Product Portfolio
Table 109. Sun Pharmaceutical Industries Ltd.: Key Strategic Moves and Developments
Table 110. Novartis International AG: Key Executives
Table 111. Novartis International AG: Company Snapshot
Table 112. Novartis International AG: Operating Segments
Table 113. Novartis International AG: Product Portfolio
Table 114. Novartis International AG: Key Strategic Moves and Developments
Table 115. Chiesi Farmaceutici S.P.A: Key Executives
Table 116. Chiesi Farmaceutici S.P.A: Company Snapshot
Table 117. Chiesi Farmaceutici S.P.A: Operating Segments
Table 118. Chiesi Farmaceutici S.P.A: Product Portfolio
Table 119. Chiesi Farmaceutici S.P.A: Key Strategic Moves and Developments
Table 120. Zydus Cadila: Key Executives
Table 121. Zydus Cadila: Company Snapshot
Table 122. Zydus Cadila: Operating Segments
Table 123. Zydus Cadila: Product Portfolio
Table 124. Zydus Cadila: Key Strategic Moves and Developments
Table 125. Cipla Inc.: Key Executives
Table 126. Cipla Inc.: Company Snapshot
Table 127. Cipla Inc.: Operating Segments
Table 128. Cipla Inc.: Product Portfolio
Table 129. Cipla Inc.: Key Strategic Moves and Developments
Table 130. Pfizer: Key Executives
Table 131. Pfizer: Company Snapshot
Table 132. Pfizer: Operating Segments
Table 133. Pfizer: Product Portfolio
Table 134. Pfizer: Key Strategic Moves and Developments
LIST OF FIGURES
Figure 1. Global Deferiprone Market, 2024 - 2033
Figure 2. Segmentation of Deferiprone Market, 2024 - 2033
Figure 3. Top Investment Pocket in Deferiprone Market
Figure 4. Moderate Bargaining Power of Buyers
Figure 5. Moderate Bargaining Power of Suppliers
Figure 6. Moderate Threat of New Entrants
Figure 7. Low Threat of Substitution
Figure 8. High Competitive Rivalry
Figure 9. Opportunities, Restraints and Drivers: Globaldeferiprone Market
Figure 10. Global Deferiprone Market Segmentation, by Form
Figure 11. Deferiprone Market for Tablets, by Country, 2024 - 2033 ($Million)
Figure 12. Deferiprone Market for Others, by Country, 2024 - 2033 ($Million)
Figure 13. Global Deferiprone Market Segmentation, by Application
Figure 14. Deferiprone Market for Transfusional Iron Overload, by Country, 2024 - 2033 ($Million)
Figure 15. Deferiprone Market for Ntdt Caused Overload. by Country, 2024 - 2033 ($Million)
Figure 16. Global Deferiprone Market Segmentation, by Distribution Channel
Figure 17. Deferiprone Market for Hospital Pharmacies, by Country, 2024 - 2033 ($Million)
Figure 18. Deferiprone Market for Drug Store Retail Pharmacies, by Country, 2024 - 2033 ($Million)
Figure 19. Deferiprone Market for Online Providers, by Country, 2024 - 2033 ($Million)
Figure 20. Top Winning Strategies, by Year, 2021-2023*
Figure 21. Top Winning Strategies, by Development, 2021-2023*
Figure 22. Top Winning Strategies, by Company, 2021-2023*
Figure 23. Product Mapping of Top 10 Players
Figure 24. Competitive Dashboard
Figure 25. Competitive Heatmap: Deferiprone Market
Figure 26. Top Player Positioning, 2023
Figure 27. Apotex Inc.: Net Sales, 2021-2023 ($Million)
Figure 28. Apotex Inc.: Revenue Share, by Segment, 2023 (%)
Figure 29. Apotex Inc.: Revenue Share, by Region, 2023 (%)
Figure 30. Cipla Limited: Net Sales, 2021-2023 ($Million)
Figure 31. Cipla Limited: Revenue Share, by Segment, 2023 (%)
Figure 32. Cipla Limited: Revenue Share, by Region, 2023 (%)
Figure 33. Vhb Life Sciences Limited: Net Sales, 2021-2023 ($Million)
Figure 34. Vhb Life Sciences Limited: Revenue Share, by Segment, 2023 (%)
Figure 35. Vhb Life Sciences Limited: Revenue Share, by Region, 2023 (%)
Figure 36. Taro Pharmaceutical Industries Ltd.: Net Sales, 2021-2023 ($Million)
Figure 37. Taro Pharmaceutical Industries Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 38. Taro Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2023 (%)
Figure 39. Sun Pharmaceutical Industries Ltd.: Net Sales, 2021-2023 ($Million)
Figure 40. Sun Pharmaceutical Industries Ltd.: Revenue Share, by Segment, 2023 (%)
Figure 41. Sun Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2023 (%)
Figure 42. Novartis International AG: Net Sales, 2021-2023 ($Million)
Figure 43. Novartis International AG: Revenue Share, by Segment, 2023 (%)
Figure 44. Novartis International AG: Revenue Share, by Region, 2023 (%)
Figure 45. Chiesi Farmaceutici S.P.A: Net Sales, 2021-2023 ($Million)
Figure 46. Chiesi Farmaceutici S.P.A: Revenue Share, by Segment, 2023 (%)
Figure 47. Chiesi Farmaceutici S.P.A: Revenue Share, by Region, 2023 (%)
Figure 48. Zydus Cadila: Net Sales, 2021-2023 ($Million)
Figure 49. Zydus Cadila: Revenue Share, by Segment, 2023 (%)
Figure 50. Zydus Cadila: Revenue Share, by Region, 2023 (%)
Figure 51. Cipla Inc.: Net Sales, 2021-2023 ($Million)
Figure 52. Cipla Inc.: Revenue Share, by Segment, 2023 (%)
Figure 53. Cipla Inc.: Revenue Share, by Region, 2023 (%)
Figure 54. Pfizer: Net Sales, 2021-2023 ($Million)
Figure 55. Pfizer: Revenue Share, by Segment, 2023 (%)
Figure 56. Pfizer: Revenue Share, by Region, 2023 (%)

Companies Mentioned

Key Market Players in the Deferiprone Market include:
  • Apotex Inc
  • Cipla Limited
  • VHB Life Sciences Limited
  • Taro Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Novartis International AG
  • Chiesi Farmaceutici S.p.A
  • Zydus Cadila
  • Cipla Inc.
  • Pfizer

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages280
PublishedJuly 2024
Forecast Period2023 - 2033
Estimated Market Value ( USD ) in 2023 $ 33.4 million
Forecasted Market Value ( USD ) by 2033 $ 45.9 million
Compound Annual Growth Rate3.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Deferiprone Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Deferiprone Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 69 Pages
  • Global
From
Deferiprone (CAS 30652-11-0) Global Market Research Report 2024 - Product Image

Deferiprone (CAS 30652-11-0) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Thalassemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 130 Pages
  • Global
From
Hemochromatosis (Iron Overload) Disease Treatment Global Market Report 2024 - Product Image

Hemochromatosis (Iron Overload) Disease Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Iron Overload Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Iron Overload Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.